SGLT2 inhibitor regulates cardiomyocyte autophagy and interferes with light chain role and mechanism of type I cardiac amyloidosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052345

Enrollment

Unknown

Registered

2021-10-24

Start date

2022-06-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac amyloidosis

Interventions

Dapagliflozin group:Dapagliflozin 10mg

placebo group :Dagglitazin simulant 10mg

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Clinical manifestations and laboratory and imaging examinations are highly suspected of CA; 2. Subendocardial myocardium or other tissue biopsy (periumbilical subcutaneous fat, tongue, kidney, rectal mucosa, bone marrow, etc.) biopsy; 3. Congo red staining is positive, and apple green birefringence can be seen under a polarized light microscope.

Exclusion criteria

Exclusion criteria: 1. Hypertrophic cardiomyopathy; 2. Dilated cardiomyopathy; 3. Aortic valve stenosis (moderate or above); 4. Severe hypertension that is difficult to control; 5. Acute or old myocardial infarction or chronic ischemic cardiomyopathy; 6. Acute myocarditis; 7. Severe liver, kidney and lung dysfunction; (eGFR<45ml/min/1.73m2); 8. Malignant tumors other than multiple myeloma are excluded; 9. Mental disorders and cognitive dysfunction.

Design outcomes

Primary

Measure	Time frame
interventricular septum thickness;NT-pro BNP;	—

Countries

China

Contacts

Public ContactBu Peili

Qilu Hospital of Shandong University

bupeili@outlook.com+86 18560086596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026